-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The neo-coronavirus COVID-19 mainly affects lung tissue and mainly causes respiratory symptoms, but studies have reported that other organ systems in new coronary patients can also suffer, including myocarditis, acute kidney injury, nervous system abnormalities and acute liver injury.
reported that in most COVID-19 patients, acute liver injury accounted for up to 76% of patients with liver bio-chemical abnormalities.
the clinical relevance of liver injury associated with COVID-19 infection is not yet known, a forward-looking study is needed on the effects of baseline liver function testing (LFT) abnormalities.
March 2020 to July 2020, the researchers looked forward to the inclusion of 275 patients with COVID-19 who had no previous liver disease.
analysis of the association between liver function (LFT) and course of illness at the time of hospitalization, severe conditions are defined as the need to be admitted to an intensive care unit (ICU) for treatment or to produce COVID-19-related deaths.
results showed that 58% of COVID-19 patients had baseline LFT abnormalities, mainly glutamate transaminase (AST) (42%), γ-glutamine transferase (GGT) (37%) and acetaminophen transferase (ALT) (27%) elevated, with low albuminemia accounting for 33%.
ALT, elevated GGT and hypoglobinemia were associated with a higher proportion of patients requiring ICU treatment and mechanical aeration.
After adjusting for age, gender, and cogeneration, the combination of low albuminemia AST or GGT abnormalities at the time of hospitalization is an important independent risk factor for ICU hospitalization (OR 46.22 and 38.8, respectively) and ICU hospitalization and/or COVID-19 comprehensive endpoint (death).
study shows that LFT abnormalities, especially GGT and albumin abnormalities, are associated with the severity of the disease when patients with new coronavirus infections are admitted to hospital.